新しい抗血栓剤

J Hirsh¹, J I Weitz

¹Hamilton Civic Hospitals Research Centre and Department of Medicine, Ontario, Canada.

Lancet (London, England)

|May 5, 1999

まとめ

新しい抗血栓剤は,ヘパリンやクマリンなどの古い薬の限界に対処しています. 新しい抗凝固剤と抗血小板薬は,血栓形成の予防に有効性と安全性が向上しています.

科学分野:

薬理学薬理学とは
バイオテクノロジーバイオテクノロジー
心血管医学心血管医学

背景:

臨床的ニーズが,先進的な抗血栓性治療法の開発を推進しています.
バイオテクノロジーは,特定の血栓形成経路を標的とした薬の作成を可能にします.
ヘパリンやクマリンのような既存の抗凝固剤は,より安全で効果的な代替品を必要とする制限があります.

研究の目的:

抗血栓剤の進歩をレビューする.
新しい抗凝固剤と抗血小板薬について議論する.
新しい薬剤の有効性および安全性プロフィールを,従来の治療法と比較するために.

主な方法:

新しい抗血栓剤の臨床評価のレビュー.
新しい薬剤の薬理学的作用機構の分析.
様々な抗血栓剤クラスの臨床結果と安全性データの比較.

主要な成果:

低分子量ヘパリンと直接的トロンビン阻害剤は,ヘパリンの限界を克服します.
トロンビンとXA因子の経口活性直接阻害剤は,クマリンを代替する有望な効果を示しています.
アデノシン・ディフォスファート受容体およびグリコプロテインIIb/IIIaアンタゴニストの阻害剤は,アスピリンよりも効果的です.

結論:

新しいバイオテクノロジーによる抗血栓剤は,改善された薬理動力学および安全性プロファイルを提供します.
新種の抗凝固剤と抗血小板薬は,血栓性疾患の管理における重要な進歩を表しています.
これらの高度な薬剤の臨床応用は拡大しており,患者のアウトカムを改善しています.

さらに関連する動画

10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

関連する概念動画

01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

関連する実験動画